As filed with the Securities and Exchange
Commission on November 12, 2020
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
Under
The Securities Act of 1933
Adicet Bio, Inc.
(Exact name of registrant as specified in its
charter)
|
|
|
Delaware |
|
81-3305277 |
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification Number)
|
500 Boylston Street, 13th Floor
Boston, MA 02116
(857) 315-5528
(Address of Principal Executive Offices)
Adicet Bio, Inc. Inducement Non-Qualified Stock Option
Agreement
(Full Title of the Plans)
Chen Schor
President and Chief Executive Officer
Adicet Bio, Inc.
500 Boylston Street, 13th Floor
Boston, MA 02116
(857) 315-5528
(Name, address, including zip code, and telephone
number, including area code, of agent for service)
Copies to:
Danielle Lauzon, Esq.
Mitchell S. Bloom, Esq.
Goodwin Procter LLP
100 Northern Avenue
Boston, Massachusetts 02210
(617) 570-1000
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated filer, a smaller
reporting company or an emerging growth company. See the
definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company,” and “emerging growth company” in Rule
12b-2 of the Exchange
Act.
|
|
|
|
|
|
|
Large accelerated filer |
|
☐ |
|
Accelerated filer |
|
☒ |
|
|
|
|
Non-accelerated filer |
|
☐ |
|
Smaller reporting company |
|
☒ |
|
|
|
|
|
|
|
|
Emerging growth company |
|
☒ |
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 7(a)(2)(B) of the
Securities Act. ☐
CALCULATION OF REGISTRATION FEE
|
|
|
|
|
|
|
|
|
|
Title of Securities
to be Registered
|
|
Amount
to be
Registered (1)
|
|
Proposed Maximum
Offering Price
per Share
|
|
Proposed Maximum
Aggregate
Offering Price
|
|
Amount of
Registration
Fee
|
Common Stock, $0.0001 par value per share
|
|
166,605 shares (2) |
|
$12.23 (3) |
|
$2,037,579.15 (3) |
|
$222.30 |
Total
|
|
166,605 shares |
|
|
|
$2,037,579.15 (3) |
|
$222.30 |
|
|
(1) |
Pursuant to Rule 416 under the Securities Act of 1933,
as amended (the “Securities Act”), this registration statement
shall also cover any additional shares of common stock, $0.0001 par
value per share (“Common Stock”) which become issuable under the
Inducement Non-Qualified
Stock Option Agreement (the “Inducement NQSO”) by reason of any
stock dividend, stock split, recapitalization or any other similar
transaction effected without the receipt of consideration which
results in an increase in the number of the Registrant’s
outstanding shares of Common Stock.
|
(2) |
Represents shares of Common Stock issuable pursuant to
the Inducement NQSO as of October 27, 2020.
|
(3) |
Represents the closing price reported for the Common
Stock on the Nasdaq Global Market on October 27, 2020.
|